跳至主要内容
临床试验/JPRN-UMIN000016045
JPRN-UMIN000016045已完成未知

A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.

Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo,0 个研究点目标入组 27 人开始时间: 2014年12月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
27

研究概览

简要总结

Combination treatment with inhaled N-acetylcysteine and oral pirfenidone reduced the rate of annual FVC decline.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • The exclusion criteria were (1) clinical features of idiopathic interstitial pneumonia other than IPF, (2) duration of pirfenidone therapy shorter than 1 month, due to adverse events, (3) poor adherence to inhaled NAC therapy, (4) an extent of emphysema greater than that of fibrotic change on HRCT, or physiological evidence of airflow obstruction, defined as a ratio of forced expiratory volume in 1 second (FEV1) to FVC of <0.7 or a residual volume >120%, and (5) evidence of coexisting respiratory infection or lung cancer

研究者

发起方
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo,

相似试验

A case-control study evaluating the efficacy and... | 临床试验